(February 21, 2014) Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients. By evaluating the therapy in cells, animals, and humans, the researchers found that a combination of … Continued
High-doses of vitamin C delivered in conjunction with IV chemotherapy may boost chemotherapy’s effectiveness and reduce side-effects in ovarian cancer treatment, according to a new study published this week. Researchers from the University of Kansas Medical Center found that patients who received vitamin C in conjunction with the conventional chemotherapy drugs paclitaxel or carboplatin reported … Continued
(February 10, 2014) Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, according to a study by scientists at the National Cancer Institute (NCI). However, further research is needed before clinical recommendations can be made. The study, which was conducted as part of the OCRF-funded Ovarian Cancer Association Consortium, … Continued
FOR IMMEDIATE RELEASE: February 7, 2014 Further Study Needed Before Clinical Recommendations Change Washington, DC—A study published yesterday by the National Institutes of Health found that women who took aspirin on a daily basis had a 20 percent reduction in risk of ovarian cancer. The Ovarian Cancer National Alliance released the following statement in response … Continued
(January 31, 2014) A new study conservatively estimates that one in five women with ovarian cancer has inherited genetic mutations that increase the risk of the disease, according to research at Washington University School of Medicine in St. Louis. Most women in the study would have been unaware of a genetic predisposition to ovarian cancer because … Continued
(January 30, 2014) OCRF grantee Yin Wang, PhD, led research which found that PKC iota signaling plays an important role in ovarian cancer development. The research, which was published in Molecular Cancer Research, also found that Auranofin, a small molecular compound, shows potential for treating ovarian cancer. The research study was funded in part by … Continued
At least 20% of women with ovarian cancer have a genetic predisposition to the disease even if they don’t have a family history ovarian cancer, according to a recent study. Researchers at Washington University School of Medicine in St. Louis analyzed the genes in ovarian cancer tumor samples from over 400 women with no family … Continued
(January 22, 2014) Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute, the Centers for Disease Control … Continued
(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve outcomes for patients with the disease. The findings were published … Continued
Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued
OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.
A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
